Group Metacognitive Therapy vs Clinical Management for Depression
NCT ID: NCT03711123
Last Updated: 2018-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
64 participants
INTERVENTIONAL
2018-11-01
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial of the Effectiveness of Metacognitive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT01608399
Group- Versus Individual-Mindfulness-Based Cognitive Therapy: a Randomized Trial
NCT02314390
Cognitive Behavior Therapy Among Patients With Major Depressive Disorder-Multiple Episodes.
NCT07300527
Mindfulness Based Cognitive Therapy for Recurrent Depression
NCT01038765
The Effect of Group Treatment for Depression: A Study of Metacognitive Therapy, Mindfulness and Support Groups
NCT02538835
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cognitive-behavioral therapy (CBT) is a well established effective recommended treatment for MDD. However, only 40-58 % of patients receiving CBT may be classified as recovered using clinical significant change assessed by the Beck Depression Inventory and only between one-third and one quarter of patients receiving CBT remain recovered 18 months after treatment.
A new treatment approach to MDD is Metacognitive Therapy (MCT). In this treatment approach, MDD is conceptualized as being maintained by rumination and meta-cognitions. Treatment seeks to challenge and change specific meta-cognitions and rumination, through behavioural experiments and verbal reattribution. There is accumulating evidence that MCT is effective in the treatment of depression, both individualized and in Groups. A recent pilot study indicated effectiveness above that of CBT. However, the results need to be tested in a randomized controlled trial with a larger sample of patients and a comparison group of active treatment.
The purpose of this trial is to evaluate the effectiveness of Group MCT treatment compared to clinical management included guided self-help and to explore which factors that are associated with depressive symptom outcome in terms of psychological factors, biomarker in terms of heart rate variabilities and polygenic risk score.
The study will be a randomized controlled, trial comprising 64 patients with a primary diagnosis of major depressive disorder (DSM-IV; American Psychiatric Association (APA), 1994). Experienced diagnosticians will assess all patients by using structural interviews such as Structured Clinical Interview for DSM-IV, axis I(SCID I), and axis II disorders (SCID II) and the Hamilton Rating Scale for Depression (HDRS).
All patients will be randomized in blocks to two groups in order to compare the following conditions: Group MCT of 10 weekly sessions lasting 90 minutes and a clinical management condition With 10 weekly individualized sessions up to 60 minutes duration.
Both between-subjects and within-subjects comparisons will be conducted. The research trial will be conducted at an outpatient specialist practice in Drammen, Norway.
The treatment will be administered according to the originators published treatment protocols for MCT for depression. Independent assessors will assess adherence and quality of treatment.
Independent experts will assess the quality of treatment by inspection of a sampling of video-recorded treatments. Using checklists session-by-session will ensure adherence of the therapy. Responsible investigator and supervisors will be using video of all treatment sessions to assess adherence to the treatment condition.
All patients referred for the study will be consecutively assessed at intake (SCID-I + II, HDRS-17). Based on diagnosis and criteria for inclusion and exclusion, the patients will be asked to volunteer to participate in the study and confirm by signing a form of consent.
Patients will be randomized to one of two conditions. Patients will be asked to self-rate symptoms on a battery of self-report questionnaires.
The patients will be assessed prior to treatment, by 10 weeks in treatment, and at six months and at one and two years of follow-up.
Reassessment of the diagnosis and symptom severity is made by post-treatment.
Criteria for recovery will be: Jacobsen criteria of a minimum change and patients crossing the cut-off point on two measures: The HDRS-17 and Beck Depression Inventory (BDI). Other outcome measures will include:
Reduction of depressive symptoms as measured by self-report questionnaires Number of patients with no MDD diagnosis based on SCID-I after treatment Relapse rate during six months and at one and two years follow-up The proportion of responders as measured by the HDRS-17 and BDI and those who no longer fulfil the conditions for a MDD diagnosis after 10 weeks (post-treatment) and by 6 months and one and two years follow-up.
The secondary efficacy variables will be the proportion of responders at 10 weeks (post-treatment) and six months and by one and two years follow-up as measured by the other symptom measures.
A comparison between the two groups of patients will be conducted at 10 weeks (post-treatment) and there will be 6 month and at one- and two years.
A within group analyses will be conducted in order to estimate effect sizes and significant clinical change estimates.
A computer provided by University of Oslo (UiO) will generate the randomization list.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group metacognitive therapy (GMCT)
10 weekly sessions of GMCT With 90 minutes duration
Group metacognitive therapy
10 weekly Group session of 90 minutes duration
Clinical Management
10 weekly individual sessions with up to 60 minutes duration
Clinical management
10 weekly individual sessions With clinical management including guided self-help
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group metacognitive therapy
10 weekly Group session of 90 minutes duration
Clinical management
10 weekly individual sessions With clinical management including guided self-help
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-65 years
* stable on medication for at least 8 weeks or medication free
* able to understand and write the Norwegian Language
* signed written informed consent prior to participation
Exclusion Criteria
* psychosis or organic mental illness
* current suicide intent
* not willing to Accept no changes in medication during treatment
* not willing to Accept random allocation
* cluster A or cluster B personality disorder
* alcohol/substance dependence/abuse
* concurrent psychological treatment or evidence based psychotherapy for depression past year
* bipolar disorder
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oslo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Toril Dammen
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Specialist practice Dr Toril Dammen
Drammen, Buskerud, Norway
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015/673-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.